Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.

Int J Chron Obstruct Pulmon Dis · 2015 · PMC4365739 · PMID 25834417

Europe PMC DOI

hedged sentence

0.0582

closest p · 1.2× alpha

0.0582

boldest claim

The sentences

borderline significantP =0.0582so close (0.05 < p ≤ 0.1)

The covariate-adjusted reduction in mean number of severe exacerbations for the roflumilast-treated group exhibited a borderline significant difference ( P =0.0582) and favorable comparison with the covariate-adjusted change in severe exacerbations for the non-roflumilast-treated group (parameter estimate, −0.1801; 95% CI −0.3664, 0.0062).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.